The European Medicines Agency (EMA) has urged that two malaria drugs, chloroquine and hydroxychloroquine, being tested as potential Covid-19 treatment, must only be used for clinical trials or national emergency use programmes.
Separately, the US Food and Drug Administration (FDA) said that these drugs are in shortage due to increased demand amid the Covid-19 pandemic.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
